- Home
- CEV vs PLRX Comparison
CEV vs PLRX Comparison
Compare CEV & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEV | PLRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 74.9M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CEV | PLRX |
|---|---|---|
| Price | $10.12 | $1.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 19.3K | ★ 422.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.35 | $1.09 |
| 52 Week High | $10.78 | $1.95 |
Technical Indicators
Market Signals| Indicator | CEV | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 48.79 |
| Support Level | $10.11 | $1.13 |
| Resistance Level | $10.22 | $1.37 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 29.17 | 57.14 |
Price Performance
Historical ComparisonAbout CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.